Quest Diagnostics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Jefferies Raises Price Target on Quest Diagnostics (DGX) to $86 Following 2Q Earnings Report
July 22, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Quest Diagnostics (NYSE: DGX), and raised the price target to $86.00 (from $75.00), following the company's 2Q earnings report. DGX posted its 3rd consecutive quarter of positive organic volume growth. However, pricing remains under pressure.
Analyst Brian Tanquilut... More
Quest Diagnostics (DGX) PT, Estimates Raised at Evercore ISI Amid Solid Q2
July 21, 2016 12:00 PM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Quest Diagnostics (NYSE: DGX) to $89.50 (from $78.50) but maintained a Hold rating following results.
The firm raised FY 2016 EPS from $5.10 to $5.15, FY 2017 EPS from $5.55 to $5.60 and FY 2018 EPS from $5.95 to $6.15.
Muken commented, "Quests turnaround momentum continues as volumes have stabilized in the LSD, with a consistent price headwind... More
Quest Diagnostics (DGX) Tops Q2 EPS by 5c; Maintains FY Adjusted EPS Outlook
July 21, 2016 6:49 AM EDTQuest Diagnostics (NYSE: DGX) reported Q2 EPS of $1.37, $0.05 better than the analyst estimate of $1.32. Revenue for the quarter came in at $1.91 billion versus the consensus estimate of $1.91 billion.
"We had another good quarter of earnings growth and a solid first half," said Steve... More
